Lör 27 nov / År 39 / Nr 4 2021

Novel Treatment for Brain Disorders

IRL has recently received approval for phase I trials with their second compound for treating brain disorders.

Integrative Research Laboratories Sweden AB (IRL) is a privately held drug discovery and development company providing novel treatments for disorders of the brain.
IRL has ten employees and has been in operation for three years. The company has a broad base of investors, both Scandinavian and international, who have invested MSEK 130 in the company. It has also received MSEK 10 in soft money. The company has huge potential, since CNS disorders are about to become one of the dominating disease areas all around the world.

”We pursue small molecule programmes targeting core disabilities in dementias, attention disorders and Parkinson’s disease using our unique systems pharmacology discovery approach, the Integrative Screening Process (ISP), to find new treatment solutions,” says Nicholas Waters of IRL.

Since the brain is a big neural network, using the standard method of single-target molecules for discovering effective treatments for brain disorders is not adequate. The great advantage of ISP is that it uses 4-8 target molecules instead of just one.

”For 20-30 years, the standard procedure has been to dissect the brain in its minutest parts in trying to understand how it works. We have a different approach. We look at the brain at the integrated level, or system level, and study the communication between its different parts, while the system is running, with the goal of achieving better effect, with less side effects,” he adds.

Registration in 2020-2022
The company recently received approval from the Swedish MPA and the ethics committee in Uppsala for phase I trials with IRL752, their second compound reaching clinical development.

”IRL752 is a cortical enhancer designed to treat Behavioural and Psychological Symptoms of Dementia (BPSD) and attention disorders,” Nicholas Waters explains.

”If we can prove good effect, we get higher royalties. Therefore, our aim is to take our substances through efficacy studies, i.e. phase II clinical trials, before we out-license them. Hopefully, both our substances are registered by 2020-2022,” he concludes.